NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
Clinical Trials
48 trialsNCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01566747 2021-12-23
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT02555748 2021-01-12
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT01649778 2020-07-15
PRINCIPAL
Novartis
Completed
NCT04462445 2020-07-10
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01221506 2020-03-26
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02014636 2020-03-03
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
Novartis
Phase 1 Completed
NCT03379012 2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03519542 2019-09-18
SOGANG
Spanish Oncology Genito-Urinary Group
Completed
NCT02729194 2019-06-10
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT01832259 2018-12-12
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
Phase 2 Completed
NCT01158521 2018-09-12
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01385228 2018-06-06
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Phase 1 Completed
NCT02282579 2018-04-26
SPAZO
Spanish Oncology Genito-Urinary Group
Completed
NCT01361113 2018-04-25
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00363194 2017-11-17
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00478725 2017-11-17
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
GlaxoSmithKline
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00401583 2017-11-13
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00992121 2017-11-13
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
Phase 1 Completed
NCT01521715 2017-08-23
FLIPPER
iOMEDICO AG
Phase 4 Completed
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00256880 2017-01-18
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
Phase 2 Completed
NCT00454571 2016-02-10
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00334282 2016-02-05
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
GlaxoSmithKline
Phase 3 Completed
NCT00731211 2015-05-20
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01446224 2015-03-27
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
GlaxoSmithKline
Completed
NCT01408004 2014-07-16
ROPETAR
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Completed
NCT00471536 2014-05-30
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01265940 2012-10-10
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder
Lukas-Krankenhaus GmbH
Phase 1/2 Completed